Roth MKM analyst Bill Kirk raised the firm’s price target on Flora Growth to $7 from $1 and keeps a Buy rating on the shares. The company’s Q4 results were similar to Q3 with legacy goodwill impairments complete, marking the symbolic transition to a more streamlined/efficient organization, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FLGC: